A phase 1 trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer.
Clinical Cancer Research, November 2015
Cynthia X Ma, Jingqin Luo, Michael Naughton, Foluso O Ademuyiwa, Rama Suresh, Malachi Griffith, Obi L Griffith, Zachary Skidmore, Nicholas C Spies, Avinash Ramu, Lee Trani, Timothy Pluard, Gayathri Nagaraj, Shana N Thomas, Zhanfang Guo, Jeremy Hoog, Jing Han, Elaine R Mardis, A. Craig Lockhart, Matthew J. Ellis
This trial was conducted to determine the maximum tolerated dose (MTD) and preliminary efficacy of buparlisib, an oral pan-class I PI3K inhibitor, plus fulvestrant in postmenopausal women with metastatic estrogen receptor positive breast cancer (ER+BC). Phase IA employed a 3+3 design to determine the MTD of buparlisib daily plus fulvestrant. Subsequent cohorts evaluated intermittent (5 of 7 day dosing) and continuous buparlisib (100mg daily). No more than 3 prior systemic treatments in the metastatic setting were allowed in Phase IB and Cohort C. Thirty one patients were enrolled. MTD was defined as buparlisib 100mg daily plus fulvestrant. Common adverse events (AEs) included fatigue (38.7 %), transaminases elevation (35.5 %), rash (29%), and diarrhea (19.4%). C-peptide was significantly increased during treatment, consistent with on-target effect of buparlisib. Compared to intermittent dosing, daily buparlisib was associated with more frequent early onset AEs and higher buparlisib plasma concentrations. Among the 29 evaluable patients, the clinical benefit rate was 58.6% (95% CI 40.7-74.5%). Response was not associated with PIK3CA mutation or treatment cohort, however loss of PTEN, progesterone receptor (PgR) expression, or mutation in TP53 was commoner in resistant cases and mutations in AKT1 and ESR1 did not exclude treatment response. Buparlisib plus fulvestrant is clinically active with manageable AEs in patients with metastatic ER+BC. Weekend breaks in buparlisib dosing reduced toxicity. Patients with PgR negative and TP53 mutation did poorly, suggesting buparlisib plus fulvestrant may not be adequately effective against tumors with these poor prognostic molecular features.
|Members of the public||2||100%|
|Readers by professional status||Count||As %|
|Student > Master||7||24%|
|Student > Ph. D. Student||5||17%|
|Student > Postgraduate||4||14%|
|Readers by discipline||Count||As %|
|Medicine and Dentistry||14||48%|
|Agricultural and Biological Sciences||6||21%|
|Biochemistry, Genetics and Molecular Biology||3||10%|
|Pharmacology, Toxicology and Pharmaceutical Science||2||7%|